Ritholtz Wealth Management Has $866,000 Stake in Takeda Pharmaceutical Co. $TAK

Ritholtz Wealth Management grew its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 149.1% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,159 shares of the company’s stock after purchasing an additional 35,413 shares during the quarter. Ritholtz Wealth Management’s holdings in Takeda Pharmaceutical were worth $866,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of TAK. Global Trust Asset Management LLC bought a new position in shares of Takeda Pharmaceutical during the third quarter valued at about $110,000. Campbell & CO Investment Adviser LLC purchased a new stake in Takeda Pharmaceutical in the 3rd quarter valued at about $673,000. Versant Capital Management Inc lifted its position in shares of Takeda Pharmaceutical by 8.3% during the 3rd quarter. Versant Capital Management Inc now owns 27,070 shares of the company’s stock worth $396,000 after buying an additional 2,074 shares in the last quarter. Bayforest Capital Ltd boosted its stake in shares of Takeda Pharmaceutical by 23.4% in the 3rd quarter. Bayforest Capital Ltd now owns 19,754 shares of the company’s stock worth $289,000 after buying an additional 3,749 shares during the last quarter. Finally, Forum Financial Management LP grew its holdings in shares of Takeda Pharmaceutical by 11.3% in the third quarter. Forum Financial Management LP now owns 102,334 shares of the company’s stock valued at $1,498,000 after acquiring an additional 10,400 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Morgan Stanley began coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $16.15 on Tuesday. The stock’s 50-day moving average is $14.97 and its 200 day moving average is $14.71. The stock has a market cap of $51.39 billion, a price-to-earnings ratio of 201.88 and a beta of 0.03. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $16.48. The company has a current ratio of 1.37, a quick ratio of 0.76 and a debt-to-equity ratio of 0.61.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.44 EPS for the quarter, hitting the consensus estimate of $0.44. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. The firm had revenue of $7.30 billion for the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. On average, sell-side analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.